AR069692A1 - Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa - Google Patents

Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa

Info

Publication number
AR069692A1
AR069692A1 ARP080105431A ARP080105431A AR069692A1 AR 069692 A1 AR069692 A1 AR 069692A1 AR P080105431 A ARP080105431 A AR P080105431A AR P080105431 A ARP080105431 A AR P080105431A AR 069692 A1 AR069692 A1 AR 069692A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
saturated
independently represent
attached form
Prior art date
Application number
ARP080105431A
Other languages
English (en)
Inventor
Mark Furber
Christopher Andrew Luckhurst
Linda Anne Stein
Hitesh Jayantilal Sanganee
Peter Alan Cage
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364478&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069692(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR069692A1 publication Critical patent/AR069692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Un proceso para su preparacion, composiciones farmacéuticas que contienen a los mismos y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica o rinitis alérgica. Reivindicacion 1: Un compuesto caracterizado porque es de la formula (1) donde n representa de manera independiente 0, 1, 2, 3 o 4; X1 representa un grupo metileno; y representa 0, 1 o 2; cada R1 representa de manera independiente halogeno, hidroxilo, carboxilo, ciano, alquilo C1-6, alcoxi C1-6, trifluorometilo, NR6R7, C(O)NR6R7, NR6aC(O)R7a, SO2NR6R7, NR6aSO2R7a o S(O)mR8 y R1 se sustituye opcionalmente con hidroxi, halogeno o alcoxi C1-6; R2 representa un átomo de hidrogeno o un grupo alquilo C1-6 opcionalmente sustituido con por lo menos un sustituyente seleccionado entre halogeno, hidroxilo, carboxilo, ciano, trifluorometilo, alquilo C1-6, cicloalquilo C3-6, NR9R10, C(O)NR11R12, NR13C(O)R14, SO2NR15R16, NR17SO2R18 y S(O)pR19; R3 representa un átomo de hidrogeno o un grupo alquilo C1-6 opcionalmente sustituido con por lo menos un sustituyente seleccionado entre halogeno, hidroxilo, carboxilo, ciano, trifluorometilo, alquilo C1-6, cicloalquilo C3-6, NR20R21, C(O)NR22R23, NR24C(O)R25, SO2NR26R27, NR28SO2R29 y S(O)pR30; R4 representa un átomo de hidrogeno o un grupo alquilo C1-6 opcionalmente sustituido con por lo menos un sustituyente seleccionado entre halogeno, hidroxilo, carboxilo, ciano, trifluorometilo, alquilo C1-6, cicloalquilo C3-6, NR31R32, C(O)NR33R34, NR35C(O)R36, SO2NR37R38, NR39SO2R40 y S(O)rR41, R5 representa un átomo de hidrogeno o un grupo alquilo C1-6 opcionalmente sustituido con por lo menos un sustituyente seleccionado entre halogeno, hidroxilo, carboxilo, ciano, trifluorometilo, alquilo C1-6, cicloalquilo C3-6, NR42R43, C(O)NR44R45, NR46C(O)R47, SO2NR48R49, NR50SO2R51 y S(O)tR52, o R3 y R4 junto con los átomos de carbono a los cuales están unidos representan un anillo ciclopropilo, o R4 y R5 junto con el átomo de carbono al cual están unidos forman un anillo carbocíclico o heterocíclico saturado o insaturado, de 3 a 6 miembros cuyo anillo se puede sustituir opcionalmente con por lo menos un sustituyente seleccionado entre halogeno, hidroxilo, carboxilo y alquilo C1-6; A y B representan, cada uno de manera independiente, un sistema de anillos aromático de 5 a 10 miembros que comprende opcionalmente por lo menos un heteroátomo del anillo seleccionado entre nitrogeno, oxígeno y azufre, el sistema de anillos está sustituido opcionalmente con por lo menos un sustituyente seleccionado entre halogeno, carboxilo, hidroxilo, oxo, nitro, ciano, mercapto, cicloalquilo C3-6, alquenilo C2-6, trifluorometilo, alcoxi C1-6, alquilcarbonilo C1-6, alquilcarboniloxi C1-6, alcoxicarbonilo C1-6, -NR53R54, -C(O)NR55R56, NR57C(O)R58, SO2NR59R60, NR61SO2R62, S(O)vR63, heterocicliloxi de 4 a 7 miembros saturado, benciloxi, alquilpiperazinilo C1-6y un grupo alquilo C1-6 (el mismo sustituido opcionalmente con hidroxilo, NR64R65, fenilo o morfolinilo); m, p, q, r, t y v representan, cada uno de manera independiente, 0, 1 o 2; X2 representa una union, un átomo de oxígeno o azufre, SO, SO2, NR66, C(O)NR66, NR66C(O), SO2NR66, NR66SO2, alquilo C1-3, etenilo o etinilo; R6 y R7 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R6 y R7 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R9 y R10 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R9 y R10 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R11 y R12 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R11 y R12 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R15 y R16 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R15 y R16 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R20 y R21 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R20 y R21 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R22 y R23 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R22 y R23 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R26 y R27 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R26 y R27 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R31 y R32 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R31 y R32 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R33 y R34 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R33 y R34 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R37 y R38 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R37 y R38 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R42 y R43 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R42 y R43 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R44 y R45 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R44 y R45 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R48 y R49 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R48 y R49 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R53 y R54 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R53 y R54 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R55 y R56 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R55 y R56 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R59 y R60 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R59 y R60 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; R64 y R65 representan, cada uno de manera independiente, hidrogeno, alquilo C1-6 o cicloalquilo C3-6, o R64 y R65 junto con el átomo de nitrogeno al cual están unidos forman un anillo heterocíclico saturado de 4 a 7 miembros; cada grupo R6a, R7a, R8, R13, R14, R17, R18, R19, R24, R25, R28, R29, R30, R35, R36, R39, R40, R41, R46, R47, R50, R51, R52, R57, R58, R61, R62 y R63 representa de manera independiente un átomo de hidrogeno o un grupo alquilo C1-6 o cicloalquilo C3-6; y R66 representa un átomo de hidrogeno o un grupo alquilo C1-6; o una sal aceptable para uso farmacéutico del mismo.
ARP080105431A 2007-12-12 2008-12-12 Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa AR069692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1297207P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
AR069692A1 true AR069692A1 (es) 2010-02-10

Family

ID=40364478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105431A AR069692A1 (es) 2007-12-12 2008-12-12 Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa

Country Status (22)

Country Link
US (2) US7902181B2 (es)
EP (1) EP2231597A1 (es)
JP (1) JP2011506421A (es)
KR (1) KR20100098683A (es)
CN (1) CN101945851B (es)
AR (1) AR069692A1 (es)
AU (1) AU2008334444B2 (es)
BR (1) BRPI0820665A2 (es)
CA (1) CA2706679A1 (es)
CL (1) CL2008003694A1 (es)
CO (1) CO6280399A2 (es)
CR (1) CR11492A (es)
DO (1) DOP2010000178A (es)
EA (1) EA201000958A1 (es)
EC (1) ECSP10010245A (es)
IL (1) IL205873A0 (es)
MX (1) MX2010006110A (es)
PE (1) PE20091100A1 (es)
TW (1) TW200932725A (es)
UY (1) UY31524A1 (es)
WO (1) WO2009074829A1 (es)
ZA (1) ZA201004091B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1976828T1 (sl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Diaminski derivati kot inhibitorji levkotrien A4 hidrolaze
CA2706679A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Novel compounds 010
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
US8633322B2 (en) 2009-10-29 2014-01-21 Janssen Pharmaceutica Nv Alkynyl derivatives useful as DPP-1 inhibitors
US8552032B2 (en) * 2009-12-18 2013-10-08 Janssen Pharmaceutica Nv Bicyclic derivatives useful as inhibitors of DPP-1
US8481547B2 (en) * 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
JP5764148B2 (ja) * 2010-03-10 2015-08-12 ヤンセン ファーマシューティカ エヌ．ベー． ジペプチジルペプチダーゼ−１（ｄｐｐ−１）の阻害剤として有用な４，４−二置換されたピペリジン誘導体
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
WO2012130299A1 (en) * 2011-03-30 2012-10-04 Prozymex A/S Peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
WO2014140078A1 (en) * 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
JP6441831B2 (ja) * 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
WO2014140081A1 (en) * 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
BR112015022227A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
EP2970283B1 (en) 2013-03-14 2020-11-11 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
CN105612149A (zh) * 2013-09-09 2016-05-25 普罗技迈克斯公司 作为二肽基肽酶i抑制剂的肽基腈化合物
NO2699580T3 (es) * 2014-01-24 2018-02-24
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
LT3191487T (lt) 2014-09-12 2019-10-10 Boehringer Ingelheim International Gmbh Katepsino c spirocikliniai inhibitoriai
DK3239143T3 (da) 2014-12-24 2023-04-11 Lg Chemical Ltd Biarylderivat som gpr120-agonist
WO2016139355A1 (en) 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
TWI691486B (zh) * 2016-01-29 2020-04-21 日商東麗股份有限公司 環狀胺衍生物及其醫藥用途
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
CN115996923A (zh) 2020-08-26 2023-04-21 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
JP2023551488A (ja) 2020-12-04 2023-12-08 瑞石生物医薬有限公司 カテプシンｃの小分子阻害剤及びその医薬的使用
JP2024505715A (ja) * 2021-02-05 2024-02-07 メッドシャイン ディスカバリー インコーポレイテッド １，４－オキサゼパンを含む縮合環誘導体
WO2023160541A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
WO2024008680A1 (en) * 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CA2379747C (en) 1999-07-30 2008-09-23 Boehringer Ingelheim Pharmaceuticals, Inc. Novel succinate derivative compounds useful as cysteine protease inhibitors
WO2001047886A1 (en) * 1999-12-24 2001-07-05 F. Hoffmann-La Roche Ag Nitrile derivatives as cathepsin k inhibitors
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ATE374181T1 (de) 2001-06-27 2007-10-15 Smithkline Beecham Corp Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
ES2298543T3 (es) * 2002-04-30 2008-05-16 Ucb Pharma, S.A. Derivados de 2,6-quinolino y 2,6-naftilo y su uso en el tratamiento de enfermedades dependientes de vla-4.
US20070099958A1 (en) 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
CA2555594A1 (en) * 2004-02-10 2005-08-25 Janssen Pharmaceutica N.V. Pyridazinones as antagonists of a4 integrins
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
CA2706679A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Novel compounds 010

Also Published As

Publication number Publication date
CL2008003694A1 (es) 2010-01-15
CO6280399A2 (es) 2011-05-20
TW200932725A (en) 2009-08-01
US20090306042A1 (en) 2009-12-10
EA201000958A1 (ru) 2010-12-30
PE20091100A1 (es) 2009-08-29
CN101945851B (zh) 2012-10-31
IL205873A0 (en) 2010-11-30
CN101945851A (zh) 2011-01-12
WO2009074829A1 (en) 2009-06-18
AU2008334444A1 (en) 2009-06-18
US7902181B2 (en) 2011-03-08
DOP2010000178A (es) 2010-09-15
CA2706679A1 (en) 2009-06-18
KR20100098683A (ko) 2010-09-08
ZA201004091B (en) 2011-11-30
UY31524A1 (es) 2009-08-03
BRPI0820665A2 (pt) 2018-05-29
EP2231597A1 (en) 2010-09-29
US20110201581A1 (en) 2011-08-18
ECSP10010245A (es) 2010-07-30
AU2008334444B2 (en) 2011-12-15
MX2010006110A (es) 2010-06-25
JP2011506421A (ja) 2011-03-03
CR11492A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
AR069692A1 (es) Peptidilnitrilos y sus usos como inhibidores de la dipeptidil peptidasa
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR076551A1 (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi
AR059521A1 (es) Ariltienopirimidinas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR059522A1 (es) Arildihidroisoquinolinas sustituidas con aminoalcoholes, procedimiento para su preparacion y su uso como medicamentos
AR070079A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
AR059520A1 (es) Derivados de ariltienopirimidinonas azaciclil sustituidas,procedimiento para su preparacion,medicamentos que las contienen y usos terapeuticos como antagonistas de receptores mch1r.
AR067478A1 (es) Compuestos derivados de morfolina pirimidina
AR104618A1 (es) Herbicidas derivados de compuestos bicíclicos sustituidos con arilo
AR064636A1 (es) Nuevos compuestos 621
AR047454A1 (es) Oxadiazoles sustituidos y composiciones farmaceuticas que los contienen.
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
AR058384A1 (es) CARBOXAMIDAS Y TIOCARBOXAMIDAS EMPLEADAS EN LA LUCHA CONTRA LOS MICROORGANISMOS INDESEABLES Y EN EL TRATAMIENTO DE SEMILLAS Y PLANTAS TRANSGÉNICAS, COMPOSICIONES QUE LAS CONTIENEN Y MÉTODO DE OBTENCIoN DE LAS MISMAS Y UN PROCEDIMIENTO PARA LA PREPARACIoN DE ESTAS CARBOXAMIDAS Y UN INTERMEDIARIO DE S
AR053352A1 (es) Heterociclos sustituidos y sus usos como inhibidores de quinasas
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
AR070571A1 (es) Derivados de amida espirociclica, composiciones farmaceuticas que los contienen, proceso de preparacion y usos de los mismos para el tratamiento de enfermedades respiratorias.
BRPI0713544B8 (pt) estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
AR050540A1 (es) Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
AR073348A1 (es) Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR067444A1 (es) Derivados de pirazinona, procesos de obtencion y composiciones farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure